5372912026-01-012026-03-315372912026-03-315372912025-03-315372912025-04-012026-03-315372912026-01-012026-03-31in-capmkt:OtherExpenses1Member5372912026-01-012026-03-31in-capmkt:OtherExpenses2Member5372912025-04-012026-03-31in-capmkt:OtherExpenses1Member5372912025-04-012026-03-31in-capmkt:OtherExpenses2Member5372912026-03-31OtherNoncurrentFinancialAssetsDomain15372912026-03-31OtherNoncurrentAssetsDomain15372912026-03-31OtherCurrentFinancialAssetsDomain15372912026-03-31OtherCurrentAssetsDomain15372912026-03-31OtherCurrentFinancialLiabilitiesDomain15372912026-01-012026-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares537291NATHBIOGENNOTLISTEDINE448G01010NATH BIO-GENES (INDIA) LIMITEDMain BoardEquity2025-04-012026-03-312026-05-042026-04-25INRLakhsQuarterlyFourth quarterSingle segmentSEED CULTIVATION2026-05-0402:00:002026-05-0416:45:00trueCash Flow IndirectDeclaration of unmodified opinion2026-01-012026-03-31AuditedConsolidated5159280002375000053967800069202100020488000-554529000420710004592800010268000271107000527354000123240001258000024904000233060001690000249960000-920000000-92000-14987000-15079000000019004000010-0.79-0.7900-0.79-0.79Notes <BR> <BR> 1. The financial results were reviewed by the Audit Committee on 02 May 2026 and were thereafter approved by the Board of Directors at its meeting held on 04 May 2026. <BR> <BR> 2. The figures for the Quarter ending 31.03.2026 are the balancing figures between audited figures of the full financial year and the year to date figures up to the third quarter. <BR> <BR> 3. The results have been consolidated with Nath Bio-Genes CA, Uzbekistan, where in the company is holding 90% of equity. <BR> <BR> 4. Short provision of Schemes of Rs. 900.00 Lakhs pertaining to the quarter ended June 2025 is adjusted in the current quarter. <BR> <BR> 5. The company is dealing with one major product segment <BR> <BR> a. Seed Cultivation <BR> <BR> 6. Investor Complaints: <BR> <BR> a. Received during the quarter - NIL <BR> <BR> b. Pending at the end of quarter-NIL <BR> <BR> 7. The figures have been regrouped/rearranged, wherever necessary2025-04-012026-03-31AuditedConsolidated4451015000781000004529115000306180100076998000-11237580003579270001598840003964200015536600004126154000402961000600740004630350004504200016900004673200004163030000000416303000-17577000398726000000019004000010661454800020.9820.980020.9820.98Selling and Distribution Expenses186684000Other Expenses84423000Selling and Distribution Expenses1224317000Other Expenses32934300024380150000205000055856000000590190000020609200026511100004264060003185593000450547600008541480007599530000016342490003248350000978700025022000778863500000109742280001900400006614548000680458800006804588000173222000000173222000494680000022269000012117930002384900012873570001311206000140079200039237910008545000146140000394695000000416964000010974228000Non Current Financial Asset206092000Other non-current assets426406000Other current financial assets1634249000Other current assets25022000Other Current Liabilities14007920000-1125317000-4213000025576800015458000000516370000001411100039642000039080000-600740000-3497690000000-1757700000-2200024430000-674100000-2110650000-159884000-6526500092840000-125730000000000000300510000120100056400000000000000000065265000003457700000000000-43460000-101413000038008000-1598840000-217963000-38134000-1292870000-1292870008889920007597050001828600018776000-3299000-1199000-14987000-17577000AuditedtrueGAUTAM N ASSOCIATES, CHARTERED ACCOUNTANTStrue2027-06-30